相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Selective recruitment of γδ T cells by a bispecific antibody for the treatment of acute myeloid leukemia
Rajkumar Ganesan et al.
LEUKEMIA (2021)
CD123 Is Consistently Expressed on NPM1-Mutated AML Cells
Vincenzo Maria Perriello et al.
CANCERS (2021)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents
Anne Sophie Kubasch et al.
LEUKEMIA (2020)
A Real-world Perspective of CD123 Expression in Acute Leukemia as Promising Biomarker to Predict Treatment Outcome in B-ALL and AML
Nupur Das et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment
Laurene Fenwarth et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant
Seongseok Yun et al.
BLOOD ADVANCES (2020)
A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis
Naveen Pemmaraju et al.
BLOOD (2020)
Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study
Farhad Ravandi et al.
BLOOD (2020)
Ameli-01: Phase I, Open Label Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), Administered in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Gail J. Roboz et al.
BLOOD (2020)
Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia
Ibrahim Aldoss et al.
BLOOD (2020)
A Phase 1b/2 Study of IMGN632, a CD123-Targeting Antibody-Drug Conjugate (ADC), As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia
Naval Daver et al.
BLOOD (2020)
Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial
Juliette Lambert et al.
HAEMATOLOGICA (2019)
Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm
Naveen Pemmaraju et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
CAR T-cell therapy: Full speed ahead
David Sermer et al.
HEMATOLOGICAL ONCOLOGY (2019)
Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm
Minas P. Economides et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2019)
A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Andrew H. Wei et al.
BLOOD (2019)
Improvement in Cytokine Release Syndrome Management for the Treatment of AML Patients with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy
Ouiam Bakkacha et al.
BLOOD (2019)
Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Paul G. Richardson et al.
BLOOD (2019)
Flotetuzumab (FLZ), an Investigational CD123 x CD3 Bispecific Dart® Protein-Induced Clustering of CD3+T Cells and CD123+AML Cells in Bone Marrow Biopsies Is Associated with Response to Treatment in Primary Refractory AML Patients
John E. Godwin et al.
BLOOD (2019)
IMGN632, a CD123-Alkylating ADC Bearing a DNA-Alkylating IGN Payload, Combines Effectively with Azacitidine and Venetoclax In Vivo, Prolonging Survival in Preclinical Models of Human Acute Myeloid Leukemia (AML)
Vinitha Mary Kuruvilla et al.
BLOOD (2019)
DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance
Katsuhiro Togami et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Naval G. Daver et al.
BLOOD (2019)
Clinical Activity and Tolerability of SL-401 (Tagraxofusp): Recombinant Diphtheria Toxin and Interleukin-3 in Hematologic Malignancies
Omar Alkharabsheh et al.
BIOMEDICINES (2019)
Characterization of SGN-CD123A, APotent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid Leukemia
Fu Li et al.
MOLECULAR CANCER THERAPEUTICS (2018)
APVO436, a bispecific anti-CD123 x anti-CD3 ADAPTIR® molecule for redirected T-cell cytotoxicity, induces potent T-cell activation, proliferation and cytotoxicity with limited cytokine release
Michael R. Comeau et al.
CANCER RESEARCH (2018)
Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy
Kenneth Jacobs et al.
BLOOD (2018)
A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells
Yelena Kovtun et al.
BLOOD ADVANCES (2018)
A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies
Naval G. Daver et al.
BLOOD (2018)
A Novel Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD123 to Treat Relapsed Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
Sanfang Tu et al.
BLOOD (2018)
Tagraxofusp Recombinant human fusion protein of diphtheria toxin and IL-3 Treatment of blastic plasmacytoid dendritic cell neoplasm
J. O'Brien et al.
DRUGS OF THE FUTURE (2018)
Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform
Muneera Al-Hussaini et al.
BLOOD (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial
Sergio Amadori et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Precision medicine in acute myeloid leukemia: Hope, hype or both?
Vinay Prasad et al.
LEUKEMIA RESEARCH (2016)
MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Gabriela Hernandez-Hoyos et al.
MOLECULAR CANCER THERAPEUTICS (2016)
IMGN632: A CD123-Targeting Antibody-Drug Conjugate (ADC) with a Novel DNA-Alkylating Payload, Is Highly Active and Prolongs Survival in Acute Myeloid Leukemia (AML) Xenograft Models
Sharlene Adams et al.
BLOOD (2016)
Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm
Tomohiro Aoki et al.
BLOOD (2015)
A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia
Daniela F. Angelini et al.
CLINICAL CANCER RESEARCH (2015)
T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia
Armen Mardiros et al.
CURRENT OPINION IN HEMATOLOGY (2015)
Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice
Erwin M. Lee et al.
HAEMATOLOGICA (2015)
A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates
Gurunadh R. Chichili et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice
Erwin M. Lee et al.
HAEMATOLOGICA (2015)
First Preclinical Report of the Efficacy and PD Results of KHK2823, a Non-Fucosylated Fully Human Monoclonal Antibody Against IL-3Rα
Tadakazu Akiyama et al.
BLOOD (2015)
Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients
Arthur E. Frankel et al.
BLOOD (2014)
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
Robert K. Hills et al.
LANCET ONCOLOGY (2014)
Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
A. Ehninger et al.
BLOOD CANCER JOURNAL (2014)
Effective and Selective Elimination of CML Stem Cells Using Novel Ethacrynic Acid Derivatives
Su Chu et al.
BLOOD (2014)
TET2 Mutations, Myelodysplastic Features, and A Distinct Immunoprofile Characterize Blastic Plasmacytoid Dendritic Cell Neoplasm in the Bone Marrow
Khaled Alayed et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study
Anjali Shah et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
The biosynthesis and biological function of diphthamide
Xiaoyang Su et al.
CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY (2013)
Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study
Livio Pagano et al.
HAEMATOLOGICA (2013)
Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007
Graca M. Dores et al.
BLOOD (2012)
CSL362: A Monoclonal Antibody to Human Interleukin-3 Receptor (CD123), Optimized for NK Cell-Mediated Cytotoxicity of AML Stem Cells
Samantha J. Busfield et al.
BLOOD (2012)
High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study
Francois Vergez et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: Results from the Hellenic Dendritic Cell Leukemia Study Group
Nikolaos J. Tsagarakis et al.
LEUKEMIA RESEARCH (2010)
Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia
Arthur Frankel et al.
LEUKEMIA & LYMPHOMA (2008)
High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group
A-L Taksin et al.
LEUKEMIA (2007)
Human mast cells express receptors for IL-3, IL-5 and GM-CSF;: a partial map of receptors on human mast cells cultured in vitro
C Dahl et al.
ALLERGY (2004)
Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors
M Gilliet et al.
ARCHIVES OF DERMATOLOGY (2004)
What is CD4+CD56+malignancy and how should it be treated?
P Reimer et al.
BONE MARROW TRANSPLANTATION (2003)
Elevated expression of IL-3Rα in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis
U Testa et al.
BLOOD (2002)
Clinical and biologic features of CD4(+)CD56(+) malignancies
J Feuillard et al.
BLOOD (2002)
The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells
CT Jordan et al.
LEUKEMIA (2000)
Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor
AE Frankel et al.
PROTEIN ENGINEERING (2000)
分享论文
